Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Why Some People Are Hesitant to Receive COVID-19 Boosters: A Systematic Review
Yam B. Limbu, Bruce A. Huhmann
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 3, pp. 159-159
Open Access | Times Cited: 40
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 9
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e074325-e074325
Open Access | Times Cited: 21
Exploring the Protective Effect of Food Drugs against Viral Diseases: Interaction of Functional Food Ingredients and SARS-CoV-2, Influenza Virus, and HSV
Andrea Ricci, Giovanni N. Roviello
Life (2023) Vol. 13, Iss. 2, pp. 402-402
Open Access | Times Cited: 19
Assessing acceptability of the fourth dose against COVID-19 among Chinese adults: A population-based survey
Chenyuan Qin, Min Du, Yaping Wang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 14
Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
M. Asante, Martin Ekholm Michelsen, Mithuna Mille Balakumar, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India
Nandini Sharma, Saurav Basu, H. B. Lalwani, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1177-1177
Open Access | Times Cited: 13
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece
Helena C. Maltezou, Dimitrios Basoulis, Konstantinos Bonelis, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2343-2348
Open Access | Times Cited: 11
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
Xiaoyin Zhang, Jiayue Xia, Lairun Jin, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 11
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial
Gonzalo Pérez Marc, Lorena M. Coria, Ana Ceballos, et al.
Vaccine (2025) Vol. 54, pp. 127045-127045
Open Access
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 9, pp. 1253-1262
Open Access | Times Cited: 6
Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial
Yawen Zhu, Rong Tang, Xiaolong Li, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 292-292
Open Access | Times Cited: 2
Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster
Tatiana A. do Nascimento, PATRÍCIA YURI NOGAMI, Camille Ferreira de Oliveira, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 792-792
Open Access | Times Cited: 2
Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel
Helena C. Maltezou, Maria N. Gamaletsou, Theodoros V. Giannouchos, et al.
Journal of Hospital Infection (2022) Vol. 132, pp. 46-51
Open Access | Times Cited: 7
Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future
Zhaomu Zeng, Xiuchao Geng, Xichao Wen, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 4
Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina
Arnulfo Garza-Silva, Diego Rivera-Salinas, Andrea Rivera-Cavazos, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives
Yu-An Kung, Chih-Hsien Chuang, Yi-Ching Chen, et al.
Journal of the Formosan Medical Association (2024)
Open Access | Times Cited: 1
Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study
Norazida Ab Rahman, Teck Long King, Kalaiarasu M. Peariasamy, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126465-126465
Closed Access | Times Cited: 1
COVID-19 Vaccination Coverage among 42,565 Adults Amid the Spread of Omicron Variant in Beijing, China
Chenyuan Qin, Min Du, Yaping Wang, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 739-739
Open Access | Times Cited: 3
The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers
Christina Reinkemeyer, Yeganeh Khazaei, Maximilian Weigert, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1574-1574
Open Access | Times Cited: 3
Sex Differences in Serious Adverse Events Reported Following Booster Doses of COVID-19 Vaccination in Thailand: A Countrywide Nested Unmatched Case-Control Study
Chawisar Janekrongtham, Mariano Salazar, Pawinee Doung‐ngern
Vaccines (2023) Vol. 11, Iss. 12, pp. 1772-1772
Open Access | Times Cited: 3
Intentions of Patients with Hypertension to Receive a Booster Dose of the COVID-19 Vaccine: A Cross-Sectional Survey in Taizhou, China
Chen-Qian Ying, Xiaoqing Lin, Li Lv, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1635-1635
Open Access | Times Cited: 5
Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods – United States, 11 December 2020 to 30 June 2022
Yuanyuan Fu, Kaipeng Wu, Zhanwei Wang, et al.
Vaccine (2023) Vol. 41, Iss. 42, pp. 6339-6349
Open Access | Times Cited: 2
Longitudinal study of disease severity and external factors in cognitive failure after COVID-19 among Indonesian population
Bumi Herman, Martin C. S. Wong, Prawat Chantharit, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top